Effect of Simvastatin on markers of triglyceride‐rich lipoproteins in familial hypercholesterolaemia
- 1 July 2002
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (7) , 493-499
- https://doi.org/10.1046/j.1365-2362.2002.01012.x
Abstract
We have previously shown elevated fasting plasma concentrations of intestinal remnants, as reflected by apolipoprotein (apo) B-48 and remnant-like particle-cholesterol (RLP-C) in patients with heterozygous familial hypercholesterolaemia (FH). We now investigate the effect of an HMG-CoA reductase inhibitor (simvastatin) on chylomicron remnant metabolism using the measurement of fasting apoB-48 and RLP-C in FH patients after long- and short-term simvastatin therapy and after a wash-out period. We also piloted the response of a breath test, involving the measurement of the fractional catabolic rate (FCR) of an intravenously injected chylomicron remnant-like emulsion labeled with cholesteryl (13)C-oleate. Fifteen FH patients were studied after > 6 months 40 mg day(-1) simvastatin treatment (long-term), a wash-out period (4 weeks), and 4 weeks of simvastatin treatment (short-term). Apolipoprotein B-48 was determined by SDS-PAGE and Western blotting/enhanced chemiluminescence and RLP-C by an immunoseparation assay. The FCR of the chylomicron remnant-like emulsion was determined from the appearance of (13)CO(2) in the breath and by multicompartmental mathematical modelling. Both long- and short-term treatment with simvastatin were associated with decreases in the plasma concentration of apoB-48 (P < 0.05) and RLP-C (P < 0.001), but there was no significant change in the FCR of the emulsion. We suggest that long- and short-term treatments with simvastatin have comparable effects in decreasing the plasma concentration of triglyceride-rich remnants in heterozygous FH, as measured by fasting apoB-48 and RLP-C. The mechanisms for this may involve decreased production of hepatic and possibly intestinal lipoproteins, and/or up-regulation of hepatic receptor clearance pathways, but these changes are apparently not associated with a change in remnant clearance as measured kinetically by the (13)CO(2) breath test.Keywords
This publication has 30 references indexed in Scilit:
- Sterol regulation of chylomicron synthesis and secretion in an intestinal epithelial cell model (CaCo-2)Atherosclerosis, 2000
- Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting stateEuropean Journal of Clinical Investigation, 1999
- Metabolic modes of action of the statins in the hyperlipoproteinemiasAtherosclerosis, 1998
- Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemiaEuropean Journal of Clinical Investigation, 1998
- Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemiaAtherosclerosis, 1998
- Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implicationsEuropean Journal of Clinical Investigation, 1995
- Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Apolipoprotein B mRNA abundance is decreased by eicosapentaenoic acid in CaCo-2 cells. Effect on the synthesis and secretion of apolipoprotein B.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Chylomicrons and chylomicron remnants in coronary artery disease: a case-control studyAtherosclerosis, 1987
- Lipoprotein receptors and cholesterol homeostasisBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1983